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Non-enzymatic glycosylation of collagen occurs both in viva during diabetes and in vitro after incubation 
with glucose. Glycosylated collagen exhibits altered physicochemical and biological properties which could 
explain some of the complications of diabetes. To provide a mechanistic explanation of this modification 
the localization of bound glucose was investigated using NaB[sH]& reduction and CNBr cleavage. 
Glucose fixation is distributed mainly on the arCB6 peptide after in vitro glycosylation whereas this 
distribution occurs less specifically during diabetes. It is concluded that fibrillogenesis alteration of in vitro 
glycosylated collagen is related to glucose fixation on free sNH2 sites normally implied in intermol~ular 
interactions. 
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1. INTRODUCTION 
The non-enzymatic glycosylation of proteins 
demonstrated for hemoglobin [ 11, lens crystallin 
121, erythrocyte membrane proteins 131, collagen 
(4,5] and others [6] is a post-translations 
modification inducing changes in physi~o~hemi~al 
properties and thus may play a role in the develop- 
ment of the late complications of diabetes. In- 
vestigations on the effect of this process on the 
physicochemical properties of collagen are, 
however, inconclusive due to the occurrence of 
associated changes such as increased cross-linking 
[7,81. 
In an attempt to investigate the precise effect of 
non-enzymatic glycosylation, in vitro glycosylated 
collagen has been used. In vitro glycosylation 
slows the rate of fibril formation and subsequently 
reduces stabilization via cross-linking [9]. 
However, this effect cannot be observed with col- 
lagen isolated from diabetic rats [7] but both in 
vitro and in vivo glycosylated collagens exhibit in- 
creased potency of inducing platelet aggregation 
[lO,ll]. These findings led us to determine the 
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distribution of non-enzymatically bound glucose in 
the CNBr peptides of in vitro and in vivo 
glycosylated type I collagen. Significant dif- 
ferences were found, possibly related to the 
observed dissimilarities in fibrillogenesis and 
physico~hemical properties. 
2. MATERIALS AND METHODS 
2.1 1 Induction of experimental diabetes in ruts and 
collagen preparation 
One-month-old male Sprague Dawley rats 
(Charles River CD strain, France) were made 
diabetic by intravenous injection of 65 mg strep- 
tozotocin (Calbiochem, A grade) per kg body wt in 
0.1 M sodium citrate buffer (pH 4.0). The animals 
were killed 5 months later, at which time the mean 
blood glucose value was 385 + 72 mgllO0 ml and 
glucosuria 8-10 g/l; only rats with bilateral 
cataract were selected. Acid-soluble collagen was 
extracted from tail tendons as in [12]. 
2.2. Preparation of in vitro glycosylated collagen 
Acid-soluble collagen obtained from 6-month- 
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old control rats was adjusted to 1 mg/ml in 
phosphate-buffered saline (PBS, pH 7.8). The 
preparation was incubated at 29°C for 25 days 
after addition of glucose to a final concentration 
of 0.17 M. Penicillin (100 II-l/ml) and strep- 
tomycin (lOOpg/ml) were added to prevent 
bacterial contamination. 
A second acidic extraction was carried out on 
the reprecipitated polymeric collagen which ap- 
peared during incubation. Insoluble residue was 
removed by centrifugation at 10000 x g for 
20 min. 
2.3. Labelling and preparation of cyanogen 
bromide peptides 
Forty mg of each sample (control, diabetic and 
in vitro glycosylated) at a concentration of 
2 mg/ml in ice-cold 0.15 M NaCl, 0.1 M sodium 
phosphate buffer (pH 7.4) were reduced by addi- 
tion of 10 mg NaBH4 containing 5.5 x 10’ Bq 
NaB[3H]H4 (Radiochemical Centre, Amersham) 
for 1 h as in [ 131. The reaction was stopped by ad- 
dition of 8 N acetic acid to lower the pH to 4.0, 
and samples were dialyzed against running deion- 
ized water cooled to 4°C for 3 days. Freeze-dried 
reduced samples were adjusted to 10 mg/ml and 
cleaved for 4 h at 30°C using a 70% formic acid 
solution containing 10 mg/ml CNBr. Each 
preparation was then diluted lo-times in deionized 
water and deaerated under vacuum for 3 h prior to 
freeze-drying. 
2.4. SDS-polyacrylamide gel electrophoresis and 
fluorography 
Samples were taken up in SDS buffer [14] and 
submitted to SDS-polyacrylamide gel elec- 
trophoresis as in [15] with a 12% acrylamide (w/v) 
gel. 
The location of tritiated peptides was done by 
fluorography as in [16] using Enhance (New 
England Nuclear) as a liquid scintillator and pre- 
flashed Fuji X-ray films. Tritium quantitation was 
carried out after excision of stained bands from the 
gel, homogenization in a Potter device, digestion 
at 60°C in Soluene 350 (Packard) then counting in 
Unisolve (Koch light) liquid scintillator .
3. RESULTS 
Fig.1 shows a typical electrophoretic pattern of 
24 
Gh c Db 
- _ .- 
GIG C Db 
-ew’ 
Fig.1. Fluorographic detection (right) of labelled CB 
peptides separated by SDS-polyacrylamide gel 
electrophoresis (left) from NaB[3H]H4-reduced collagen: 
in vitro glycosylated (Glc), control (C), diabetic (Db). 
the major cyanogen bromide (CB) peptides of 
acid-soluble type I collagen. This appears unaf- 
fected by either in vivo or in vitro glycosylation. 
c&B6a and arCB3-5 peptides which both contain 
tyrosyl residues were identified on the acrylamide 
gels by 1251 labelling prior to CNBr cleavage. As 
described in [17] arCB6 runs as a doublet. 1251- 
labelled LuiCB6a corresponds to the intact peptide 
and has a higher A4,. Unlabelled arCB6b results 
from partial hydrolysis during the experimental 
procedure and may appear as the major compo- 
nent after electrophoresis (fig.1). 
Fluorography (fig. 1) and tritium quantitation of 
NaB[3H]H4-reduced samples (table 1) demonstrate 
significant differences in tritium partition on the 
different peptides. To achieve maximal fluoro- 
graphic resolution, the same amount of radio- 
activity was applied on the acrylamide gel so that 
the peptide content differed greatly from one sam- 
ple to another because of changes in total specific 
activity (specific activity for normal = 1300 Bq/mg, 
diabetic = 2500 Bq/mg, in vitro glycosylated = 
3400 Bq/mg). 
Control collagen contains highly labelled 
cuiCB6a (30% of the sample radioactivity); 
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Table 1 
Quantitation of the specific activities of CB peptides obtained from reduced collagens 
May 1984 
Collagen Peptide 
luzCB3-5 (rlCB6-7 0qZB3-7 (YICB~-4 c&B4 cu1CB7 (Y,CB~ arCB6a LurCBtib a1CB3 
Control 
Diabetic 
In vitro 
glycosylated 
2.6 2.0 5.0 2.2 1.9 1.5 2.0 8.1 1.4 0.9 
6.1 3.3 7.0 4.3 13.2 8.8 3.7 6.8 5.9 1.2 
13.4 7.6 20 12.8 29.8 18.4 11.3 8.9 17.7 2.6 
Values are expressed in Bq 
aiCB3-7 and to a less extent (w&B&7 also exhibits 
some radioactivity. 
In the sample from diabetics, cviCB6a was poor- 
ly labelled. The radioactivity was mainly 
distributed on fractions c~zCB4 (20%), rGB3-7 
and cuiCB7. 
In vitro glycosylated collagen also contains 
several abelled peptides including cuiCB6b (1901o), 
c&B4 (2lOro), curCB3-7 (14%) and to a smaller ex- 
tent arCB7 and culCB8. 
These results were confirmed by CNBr cleavage 
and fluorography of collagen previously incubated 
with [U-14C]glucose then reduced with unlabelled 
NaBH4. In this case, the distribution was similar to 
fluorography performed after NaBH4 reduction; 
however, we observed an additional radioactive 
band between criCB3-7 and ruzCB2-4 peptides (not 
shown). This radioactive fraction was further iden- 
tified as a contaminant in labelled glucose reported 
in [18]. 
4. DISCUSSION 
In control collagen a high level of tritium activi- 
ty is found on the cuiCB6a peptide, i.e., the minor 
peptidic fraction of the (rrCB6 doublet. cuiCB6a 
differs from cuiCB6b only by an additive peptide 
identified as the carboxyteiopeptidic end of cyr 
chains. The negligible amount of radioactivity 
associated with ruiCB6b demonstrates that no 
glucose fixation occurs in this part of the molecule 
despite the presence of 5 potentially glycosylatable 
r-amino groups 1191. Therefore the telopeptide 
preferentially binds tritium although it does not 
contain any glycosylatable group, but it does con- 
tain the reducible allysine 1044 normally implied in 
the intermolecular dehydrohydroxylysinonorleu- 
tine cross-link 1201. 
The low amount of tritium observed in t~tCB3-7 
and aiCB6-7 must be related to the slight glucose 
fixation previously reported during aging in 
physiological conditions 1211, since no reducible 
precursors are present in this part of the cyr chains. 
In samples from diabetics the labelling is 
distributed mainly on the domain which contains 7 
lysyl and four hydroxylysyl residues. The low ac- 
tivity observed in c&Bfia could be related to the 
lesser amount of this peptide sampled in the gel as 
compared to control collagen. In other CNBr pep- 
tides including curCBBb, the distribution of the 
radioactivity appears in relation with the density of 
free c-NH2 groups, probably due to the non- 
enzymatic glucose fixation. 
After in vitro non-enzymatic glycosylation 
specific activity increases by 250% as referred to 
control collagen and tritium is mainly found on 
m&B4 and (rrCB6. As described above for col- 
lagen from diabetics, the high content in 
glycosylatabie eNH2 groups would entail both in 
vivo and in vitro glucose fixation via the reducible 
glycosylamines in a2CB4. 
In triCB6 radioactivity is essentially located in 
crtCB6b, pointing out the occurrence of reducible 
glycosylamines. Even when the labelling intensity 
is referred to the potentially glycosylatable c-amino 
groups (fig.2) this peptide appears to be a privileg- 
ed target for in vitro glucose fixation. A 
mechanistic explanation would imply the HYL930 
residue which is known to react with allysine 9 
leading to the dehydrohydroxylysinonorleucine _. 
cross-link. Acetic acid extraction of collagen prior 
to incubation with glucose results in the recovery 
of hydroxylysine 930 and the reactivity of this 
residue towards glucose should be markedly in- 
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Fig.2 Distribution of tritium activity in the CB peptides 
of NaB[3H]tI,+-reduced collagen: control (C), in vitro 
glycosylated (Glc), diabetic (Db). Data are expressed as 
the specific activities referred to the potentially 
glycosylatable c-amino groups. 
creased due to the similarity between the E-N- 
glycosylation and cross-linking processes (fig.3). 
Such an hypothesis is supported by the low glucose 
fixation observed in rurCB6b from diabetic col- 
lagen, probably as a consequence of the 
preestablished cross-links. 
A recent report (221 claimed that in vitro 
glycosyiation would occur along the entire length 
of the collagen chains without site specificity. This 
disagrees with our rest&s which give evidence for 
an ordered glucose fixation which differs from in 
vitro to in vivo glycosylated collagen. Such an 
orientated glycosylation could be related to the 
observed dissimilarities in the physico~hemi~a~ 
properties of these two types of glycosylated col- 
lagen [7,9]. For example, the directed fixation of 
glucose on sites of in vitro glycosylated collagen 
normaIly implied in cross-linkage may be proposed 
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Fig.3. Comparative reaction scheme for e-N-glycosylation (a) and cross-link formation (b). 
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as an explanation for the previously observed 
alterations of fibrillogenesis parameters and for 
the absence of fiber stabilization via cross-linking 
of in vitro glycosylated collagen [9]. 
The use of in vitro glycosylation, since it 
eliminates metabolic consequences of diabetes 
[23], allowed us to demonstrate the direct effect of 
glucose fixation in the increased platelet ag- 
gregating potency of collagen observed in diabetes 
[lo]. Platelet adhesion and aggregation to collagen 
are closely dependent on the state of polymeriza- 
tion of collagen fibrils [24] and this cell-matrix in- 
teraction is known to imply specific domains of the 
molecule [25,26]. This localization of the bound 
glucose both in vivo and in vitro would thus permit 
a better understanding of the altered biological 
properties of glycosylated collagen which 
represents an important thrombotic risk during 
diabetes. 
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